Massachusetts Rx investigation
Executive Summary
Lilly and Barr join list of companies disclosing subpoenas from the Massachusetts U.S. attorneys office investigation into pricing and reimbursement. Lilly specifies that the March subpoena relates to "pricing and Medicaid reimbursement of company products in Massachusetts." The healthcare fraud unit in Boston appears close to a large settlement with TAP related to marketing and pricing practices (1"The Pink Sheet" April 23, p. 6)
You may also be interested in...
Rx Sampling In "Spotlight" Of Boston Grand Jury As Part Of TAP Investigation
Pharmaceutical companies should consider how their sampling programs will look in "the very bright spotlight of a federal grand jury investigation," Boston Assistant U.S. Attorney Michael Loucks said during the Food & Drug Law Institute annual meeting April 19 in Washington, D.C.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials